Amplitude Surgical - Consolidated Annual Sales of €106.0m, up +6.3% at Constant Exchange Rates

Growth of 7.0% at constant exchange rates in the fourth quarter of FY 2023-2024 and 6.3% for the full year
5.0% sales growth in France
Good momentum outside France, with sales up 9.9% at constant exchange rates

Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its consolidated sales for fiscal year 2023-24.

Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "Group sales for the 2023-24 financial year were up +6.3% at constant exchange rates on the previous year. Amplitude Surgical has thus recorded another year of business growth, both in France, with a +5.0% increase in sales, and internationally, where sales momentum is up +9.9% at constant exchange rates".

Consolidated sales for the 2023-2024 financial year

Sales 2023-24

30/06/2024

30/06/2023

Change at current exchange rates

Change at constant exchange rates

In € thousands - IFRS

Knee and hip activities

106,029

100,201

5.8%

6.3%

Total

106,029

100,201

5.8%

6.3%

Sales Q4 2023-24

30/06/2024

30/06/2023

Change at current exchange rates

Change at constant exchange rates

In € thousands - IFRS

Knee and hip activities

26,416

24,784

6.6%

7.0%

Total

26,416

24,784

6.6%

7.0%

In the 2023-24 financial year, Amplitude Surgical sales came to €106.0 million, up 5.8% and 6.3% at constant exchange rates.

The Group's business growth is slightly below the 7% announced in April 2024, as the last few months of activity in France were punctually negatively impacted by strikes in some private clinics, as well as by a drop in scheduling in the weeks preceding the elections.

In FY 2023-24, sales in France rose by 5.0%, while international distributors grew by 7.4% and the Group's international subsidiaries by 8.1% at current exchange rates and 10.7% at constant exchange rates.

Amplitude Surgical's direct sales (French market and international subsidiaries), which account for almost 93% of total Group sales, rose by +6.3% at constant exchange rates.

In France, the Group benefited from a favorable sales momentum throughout the year, except in the last quarter. France accounts for around 72% of Group sales.

For international subsidiaries, sales were up at constant exchange rates in Belgium, Australia and Brazil, while sales in Switzerland and South Africa were down.

Next press release:

Annual results 2023-24: Wednesday, October 23, 2024, after market close.

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for orthopedic surgical technologies for the lower limbs. Amplitude Surgical develops and markets high-end products for orthopedic surgery, covering the main pathologies affecting the hip and knee. Working in close collaboration with surgeons, Amplitude Surgical develops numerous high value-added innovations to best meet the needs of patients, surgeons and care facilities. A leading player in France, Amplitude Surgical is expanding internationally through its subsidiaries and a network of agents and exclusive distributors in over 30 countries. At June 30, 2024, Amplitude Surgical had 428 employees and sales of nearly 106.0 million euros.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240725489139/en/

Amplitude Surgical Chief Financial Officer Dimitri Borchtch finances@amplitude-surgical.com 04 75 41 87 41

NewCap Investor Relations Thomas Grojean amplitude@newcap.eu 01 44 71 94 94

NewCap Media Relations Nicolas Merigeau amplitude@newcap.eu 01 44 71 94 98

Amplitude Surgical (EU:AMPLI)
過去株価チャート
から 6 2024 まで 7 2024